107 related articles for article (PubMed ID: 27446875)
1. Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian Aboriginal.
Parmar P; Corsi DJ; Cooper C
Can J Gastroenterol Hepatol; 2016; 2016():8987976. PubMed ID: 27446875
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999-2004.
Wu HX; Wu J; Wong T; Andonov A; Li Q; Dinner K; Donaldson T; Paton S;
Eur J Clin Microbiol Infect Dis; 2007 Mar; 26(3):167-74. PubMed ID: 17308895
[TBL] [Abstract][Full Text] [Related]
3. The interaction of ethnicity and chronic disease as risk factors for osteoporotic fractures: a comparison in Canadian Aboriginals and non-Aboriginals.
Leslie WD; Derksen S; Prior HJ; Lix LM; Metge C; O'neil J
Osteoporos Int; 2006; 17(9):1358-68. PubMed ID: 16770522
[TBL] [Abstract][Full Text] [Related]
4. Viral hepatitis in the Canadian Inuit and First Nations populations.
Minuk GY; Uhanova J
Can J Gastroenterol; 2003 Dec; 17(12):707-12. PubMed ID: 14679425
[TBL] [Abstract][Full Text] [Related]
5. High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.
Kieran J; Dillon A; Farrell G; Jackson A; Norris S; Mulcahy F; Bergin C
Int J STD AIDS; 2011 Oct; 22(10):571-6. PubMed ID: 21998177
[TBL] [Abstract][Full Text] [Related]
6. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
[TBL] [Abstract][Full Text] [Related]
7. Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations.
Miller CL; Spittal PM; Wood E; Chan K; Schechter MT; Montaner JS; Hogg RS
AIDS Care; 2006 Nov; 18(8):968-76. PubMed ID: 17012087
[TBL] [Abstract][Full Text] [Related]
8. The Cedar Project: a comparison of HIV-related vulnerabilities amongst young Aboriginal women surviving drug use and sex work in two Canadian cities.
Mehrabadi A; Craib KJ; Patterson K; Adam W; Moniruzzaman A; Ward-Burkitt B; Schechter MT; Spittal PM;
Int J Drug Policy; 2008 Apr; 19(2):159-68. PubMed ID: 17870461
[TBL] [Abstract][Full Text] [Related]
9. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
[TBL] [Abstract][Full Text] [Related]
10. Risk indicators associated with injection drug use in the Aboriginal population.
Lemstra M; Rogers M; Thompson A; Moraros J; Buckingham R
AIDS Care; 2012; 24(11):1416-24. PubMed ID: 22292863
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
[TBL] [Abstract][Full Text] [Related]
12. First Nations hepatitis C virus infections: Six-year retrospective study of on-reserve rates of newly reported infections in northwestern Ontario.
Gordon J; Bocking N; Pouteau K; Farrell T; Ryan G; Kelly L
Can Fam Physician; 2017 Nov; 63(11):e488-e494. PubMed ID: 29138174
[TBL] [Abstract][Full Text] [Related]
13. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Selvapatt N; Habibi MS; Brown A
J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
[TBL] [Abstract][Full Text] [Related]
14. The epidemiology of hepatitis C in a Canadian Indigenous population.
Uhanova J; Tate RB; Tataryn DJ; Minuk GY
Can J Gastroenterol; 2013 Jun; 27(6):336-40. PubMed ID: 23781516
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.
Mohsen AH; Murad S; Easterbrook PJ
HIV Med; 2005 May; 6(3):206-15. PubMed ID: 15876288
[TBL] [Abstract][Full Text] [Related]
16. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
Solà R; Galeras JA; Montoliu S; Tural C; Force L; Torra S; Montull S; Castro ER; Coll S; Fuster D; Barrufet P; Sirera G; Giménez MD; Clotet B; Planas R
AIDS Res Hum Retroviruses; 2006 May; 22(5):393-400. PubMed ID: 16706615
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America.
Rempel JD; Uhanova J
Viruses; 2012 Dec; 4(12):3912-31. PubMed ID: 23342378
[TBL] [Abstract][Full Text] [Related]
18. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
19. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
20. Use and outcomes of peritoneal dialysis among Aboriginal people in Canada.
Tonelli M; Hemmelgarn B; Manns B; Davison S; Bohm C; Gourishankar S; Pylypchuk G; Yeates K; Gill JS
J Am Soc Nephrol; 2005 Feb; 16(2):482-8. PubMed ID: 15590757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
